ENDP stock: buy or sell?
January 24th, 2020
Endo International plc develops, manufactures, and distributes pharmaceutical products and devices worldwide. Its U.S. Generic Pharmaceuticals segment provides tablets, capsules, powders, injectables, liquids, nasal sprays, ophthalmics, and transdermal patches for pain management, urology, central nervous system disorders, immunosuppression, oncology, women's health, and cardiovascular disease markets.
Should I buy ENDP stock?Even if you are a experienced or a novel trader, best trading results come from using an investing strategy that never leaves to random or subjective opinions when is the best moment to buy or sell stocks. That's why is so important to choose your own trading strategy that matches with your character as inversor. At Stocks2.com, we like to use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.
Currently, Endo International stock doesn't match any of these trading strategies, so our recommendation is not to buy.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Endo International stock a buy?
Financial institutions and banks post stock ratings everyday.At Stocks2.com, we detected 13 ratings published for ENDP stock in the last 30 days.
|Date||Analyst / Broker||Previous rating||Current rating|
|2019-8-8||Royal Bank of Canada||n/a||Hold|
|2019-7-15||Morgan Stanley||Equal Weight||Underweight|
|2019-7-11||Royal Bank of Canada||Outperform||Sector Perform|
|2019-5-13||JPMorgan Chase & Co.||Neutral||Underweight|
|2019-3-5||Svb Leerink||Outperform||Market Perform|
|2019-3-5||Leerink Swann||Outperform||Market Perform|
|2019-3-18||JPMorgan Chase & Co.||Neutral||Neutral|
ENDP stock analysis
Shares of Endo International ended on Jan/24 at $5.92 and collapsed a chilling -10.30%.
Shares of Endo International ended on January/24 at $5.92 and collapsed a chilling -10.30%. Since price and SMA200d lines crossed up on January 13th, ENDP climbed $1.37 (30.11%). From a daily perspective, ENDP is in a short term uptrend after plotting its last bottom ($4.32, on Jan 8th) higher than the previous bottom, and its last top ($6.73, on Thursday) also over the previous top. Now trading in between its last bottom and last top ENDP might consolidate in a plain range, waiting to break out over $6.73 or down under $4.32. Since SMA50d and SMA100d crossed up on October, ENDP price climbed $1.42 per share (31.56%).
After boosting an amazing 24.67% in a week last week, Endo International closed this week at $5.92 and decreased a rough -1.99%. Late December 2019 ENDP collapsed a bloodcurdling -11.91% in just one week.
Endo International shows a strong mid-term uptrend with several rising tops and rising bottoms. Since its last bottom late December 2019, ENDP stock climbed unceasignly breaking out above its last top at $5.76. Since SMA20w and SMA40w crossed up this week, ENDP price slid a -1.99%. Trading stocks that are under the 40-weeks (that is, 200-days) moving average mark is not recommended by many experts, as it indicates that the stock has not enough institutional support.
ENDP stock price history
ENDP stock went public on July 18th, 2000 with a price of $14.501. Since then, ENDP stock sliced a -59.20%, with a yearly average of -3.10%.
1: Adjusted price after possible price splits or reverse-splits.
ENDP stock historical price chart
ENDP stock reached 52-week highs on February at $12.49, and all-time highs 2015-04-16 with a price of 96.58.
ENDP stock price target is $6.20Nobody can reliably foresee how stock prices may evolve in the future. However, banks and other financial institutions analysts, with the help of lots of data and algorithms do their best to predict the stock prices movement. The accuracy of these stock price predictions is not very high, and you should not blindly believe and make decisions only based on what this ratings or price target predictions say. We found 10 price forecasts for ENDP stock released in the last month:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-8-8||Royal Bank of Canada||Reiterates||n/a||$6.00||-|
|2019-7-11||Royal Bank of Canada||Downgrades||$11.00||$6.00||-45.5%|
|2019-5-13||JPMorgan Chase & Co.||Downgrades||n/a||$9.00||-|
|2019-3-18||JPMorgan Chase & Co.||Lowers Target||$16.00||$10.00||-37.5%|
Financials and fundamental analysis
Earnings date and Earnings per ShareOn February, Endo International presented its financial report, posting an outstanding growth for the Earnings per Share (EPS) ratio. Analyst were expecting $0.59 per share, but Endo International posted $0.75.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsIn 2018, Endo International annual sales collapsed a chilling -15.04% to $2,947.08 M USD from $3,468.86 marked in 2017. In contrast, its profit margin (compared to sales) rocketed to -35.00%, that is $-1,031.47 million.
|2013||$2,620 M||-||$-535.50 M-20.4%||-|
|2014||$2,877 M||9.82%||$-721.32 M-25.1%||34.70%|
|2015||$3,269 M||13.61%||$-1,495.04 M-45.7%||107.26%|
|2016||$4,010 M||22.69%||$-3,347.07 M-83.5%||123.88%|
|2017||$3,469 M||-13.50%||$-2,035.43 M-58.7%||-39.19%|
|2018||$2,947 M||-15.04%||$-1,031.47 M-35.0%||-49.32%|
Quarterly financial resultsEndo International reported $786.39 million in sales for 2018-Q4, a 5.49% up compared to previous quarter. Reported quarter income marked $-291.91 million with a profit margin of -37.12%. Profit margin plunged a -13.89% compared to previous quarter when profit margin was -23.23%. When comparing revenues to same quarter last year, Endo International sales marked a slightly fine gain and gained a 2.31%. Looking back to recent quarterly results, Endo International posted 3 negative quarters in a row.
|2017-Q1||$1,040 M||-||$-165.42 M-15.9%||-|
|2017-Q2||$876 M||-15.80%||$-696.02 M-79.5%||320.76%|
|2017-Q3||$787 M||-10.15%||$-96.67 M-12.3%||-86.11%|
|2017-Q4||$769 M||-2.32%||$-368.42 M-47.9%||281.11%|
|2018-Q1||$701 M||-8.86%||$-505.49 M-72.2%||37.21%|
|2018-Q2||$715 M||2.02%||$-60.87 M-8.5%||-87.96%|
|2018-Q3||$745 M||4.31%||$-173.21 M-23.2%||184.56%|
|2018-Q4||$786 M||5.49%||$-291.91 M-37.1%||68.53%|
Endo International ownershipWhen you are planning to invest in a stock, it's always worth to overview its ownership structure.
Endo International shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a of all shares.
For a better understanding, the next table shows ownership data compared to other related companies:
|Market cap||$0.0 M|
|Total shares||0.0 M|
|Float shares||0.0 M|
|- Institutional holdings (%)||0.0%|
|- Insider holdings (%)||0.0%|
|Shares in short selling||0.0%|
|Friday, January 24th, 2020|
|Day range||$5.87 - $6.66|
|Average true range||$0.44|
|50d mov avg||$4.89|
|100d mov avg||$4.38|
|200d mov avg||$4.59|
Endo International performanceTo measure stock performance is always good to benchmark with competitors or related stocks. We compared Endo International against in the following table: